Nonglin Mel
Family Medicine · Jamaica, NYNPI 1760619993
Payments from drug & device makers
Across 291 payments — averaging $62.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12K
- Viiv Healthcare Company$4K
- Johnson & Johnson$960
- Janssen Products, LP$398
- AbbVie$282
- Merck$163
- plus $322 from 6 others
What the payments were for
- Speaking & faculty fees$8,10045%
- Travel & lodging$1,76010%
- Food & beverage$8,11045%
- Education$1921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 79 | $12,186 |
| Viiv Healthcare Company | 115 | $3,852 |
| Johnson & Johnson(2 entities) | 72 | $960 |
| Janssen Products, LP | 4 | $398 |
| AbbVie | 6 | $282 |
| Merck | 6 | $163 |
| AstraZeneca | 1 | $125 |
| EMD Serono, Inc. | 4 | $112 |
| Theratechnologies Inc. | 1 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,163 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 603 | $2,345,241 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 190 | $904,934 |
| DescovyEmtricitabine/Tenofov Alafenam | 158 | $333,038 |
| TivicayDolutegravir Sodium | 136 | $332,466 |
| JulucaDolutegravir/Rilpivirine | 96 | $327,882 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 61 | $224,574 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 54 | $211,481 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 44 | $150,334 |
| PrezcobixDarunavir/Cobicistat | 55 | $138,588 |
| DovatoDolutegravir Sodium/Lamivudine | 42 | $123,746 |
| RybelsusSemaglutide | 90 | $109,894 |
| JardianceEmpagliflozin | 87 | $73,021 |
| CabenuvaCabotegravir/Rilpivirine | 11 | $70,973 |
| OzempicSemaglutide | 33 | $50,257 |
| PifeltroDoravirine | 20 | $44,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $12,186 | $2,889,760815 claims |
| Viiv Healthcare CompanyTivicay, Juluca, Triumeq, Dovato, Cabenuva | $3,852 | $1,079,640346 claims |
| Janssen Products, LPSymtuza | $398 | $904,934190 claims |
| Johnson & JohnsonPrezcobix | $960 | $138,58855 claims |
| MerckPifeltro, Isentress, Januvia, Janumet | $163 | $108,80272 claims |
| AstraZenecaFarxiga | $125 | $33,18635 claims |
| PfizerEliquis | $19 | $24,76229 claims |
| NovartisEntresto | $14 | $21,92812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Jamaica
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.